HK inno.N Corporation

🇰🇷South Korea

Country: 🇰🇷South Korea

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

This Study Aims to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties and Food Effect of IN-114199 in Healthy Participants

Phase 1

Not yet recruiting

Conditions: Chronic Idiopathic Constipation

Interventions: Drug: IN-114199 10mg or placebo
Drug: IN-114199 20mg or placebo
Drug: IN-114199 2.5mg or placebo
Drug: IN-114199 5mg or placebo
Drug: IN-114199 40mg or placebo

First Posted Date: 2024-12-17

Last Posted Date: 2024-12-17

Lead Sponsor: HK inno.N Corporation

Target Recruit Count: 80

Registration Number: NCT06736912

Locations: 🇰🇷
Seoul National University Hospital, Clinical Trial Center, Seoul, Korea, Republic of

To Compare the Pharmacokinetics and Safety After a Single Dose Administration of IN-G00002 and IN-R00002 in Healthy Adult Volunteers

Phase 1

Active, not recruiting

Conditions: Non-valvular Atrial Fibrillation (NVAF)

Interventions: Drug: IN-R00002
Drug: IN-G00002

First Posted Date: 2024-12-10

Last Posted Date: 2024-12-10

Lead Sponsor: HK inno.N Corporation

Target Recruit Count: 60

Registration Number: NCT06725355

Locations: 🇰🇷
Central Hospital, Clinical Trial Center, Siheung, Korea, Republic of

Long-term Observational Study to Evaluate the DFS and OS of Adjuvant FOLFIRINOX Regimen in Pancreatic Cancer Patients

Recruiting

Conditions: Adjuvant Chemotherapy

First Posted Date: 2024-04-29

Last Posted Date: 2024-04-29

Lead Sponsor: HK inno.N Corporation

Target Recruit Count: 36

Registration Number: NCT06389552

Locations: 🇰🇷
Seoul ST. Mary's Hospital, Seoul, Korea, Republic of

PK, PD and Safety of Tegoprazan 12.5 mg After Oral Administration in Healthy Subjects

Phase 1

Conditions: Healthy

Interventions: Drug: Tegoprazan 12.5mg
Drug: Tegoprazan 25mg
Drug: Famotidine 20mg

First Posted Date: 2024-03-27

Last Posted Date: 2024-03-27

Lead Sponsor: HK inno.N Corporation

Target Recruit Count: 36

Registration Number: NCT06332638

Locations: 🇰🇷
Inje University Busan Paik Hospital, Busan, Korea, Republic of

Effect of Tegoprazan on Pharmacodynamics of Clopidogrel in Healthy Subjects

Phase 1

Not yet recruiting

Conditions: Healthy

Interventions: Drug: Clopidogrel 75 mg
Drug: Tegoprazan 25 mg
Drug: Esomeprazole 20mg

First Posted Date: 2023-12-11

Last Posted Date: 2023-12-11

Lead Sponsor: HK inno.N Corporation

Target Recruit Count: 48

Registration Number: NCT06164834

Locations: 🇰🇷
Seoul National University Hospital, Clinical Trial Center, Seoul, Korea, Republic of

Exploratory Study to Standard Triple Therapy With Tegoprazan(by Dose) in H. Pylori Positive Patients

Phase 2

Recruiting

Conditions: Helicobacter Pylori Infection

Interventions: Drug: Tegoprazan 50 mg Triple Therapy
Drug: Tegoprazan 100 mg Triple Therapy
Drug: Lansoprazole Triple Therapy

First Posted Date: 2023-07-06

Last Posted Date: 2023-07-06

Lead Sponsor: HK inno.N Corporation

Target Recruit Count: 381

Registration Number: NCT05933031

Locations: 🇰🇷
Chung-Ang University Hosptial, Seoul, Korea, Republic of

A Study to Evaluate the Safety, Tolerability and Pharmacokinetic Properties of IN-A002 Ointment in Healthy Adult Male Volunteers and Mild to Moderate Atopic Dermatitis Patients

Phase 1

Not yet recruiting

Conditions: Mild to Moderate Atopic Dermatitis

Interventions: Drug: IN-A002 Ointment 0.5% or IN-A002 Placebo Ointment
Drug: IN-A002 Ointment 1% or IN-A002 Placebo Ointment
Drug: IN-A002 Ointment 3%
Drug: Elidel Cream 1% (pimecrolimus)
Drug: IN-A002 Ointment 0.3% or IN-A002 Placebo Ointment
Drug: IN-A002 Ointment 3% or IN-A002 Placebo Ointment
Drug: IN-A002 Ointment 5% or IN-A002 Placebo Ointment
Drug: IN-A002 Ointment 1%

First Posted Date: 2023-02-15

Last Posted Date: 2023-02-15

Lead Sponsor: HK inno.N Corporation

Target Recruit Count: 80

Registration Number: NCT05729074

PK and PD Interaction Between Tegoprazan and NOACs After Multiple Oral Dosing in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Edoxaban 60mg
Drug: Tegoprazan 50mg
Drug: Apixaban 5mg
Drug: Rivaroxaban 20mg

First Posted Date: 2023-02-10

Last Posted Date: 2023-12-11

Lead Sponsor: HK inno.N Corporation

Target Recruit Count: 87

Registration Number: NCT05723510

Locations: 🇰🇷
Jeonbuk National University Hospital, Jeonju, Korea, Republic of

A Study to Evaluate the Efficacy and Safety of Tegoprazan in GERD Patients With Nighttime Heartburn

Phase 4

Recruiting

Conditions: Gastroesophageal Reflux Disease

Interventions: Drug: Esomeprazole
Drug: Tegoprazan

First Posted Date: 2023-01-27

Last Posted Date: 2023-08-03

Lead Sponsor: HK inno.N Corporation

Target Recruit Count: 338

Registration Number: NCT05701540

Locations: 🇰🇷
Severance Hospital, Seoul, Korea, Republic of

A Study to Evaluate Effect of IN-A001 on Pharmacokinetics of Tacrolimus in Healthy Volunteers

Phase 1

Conditions: Healthy

Interventions: Drug: Tacrolimus
Drug: IN-A001(Tegoprazan)
Drug: IN-A001(Tegoprazan) + Tacrolimus

First Posted Date: 2022-04-29

Last Posted Date: 2022-04-29

Lead Sponsor: HK inno.N Corporation

Target Recruit Count: 12

Registration Number: NCT05353010

Locations: 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy